TCI Bio

TCI Bio, legally TCI Co., Ltd., is a Taiwan-based contract development and manufacturing organization (CDMO) focused on functional beverages, dietary supplements, nutraceutical ingredients, and skincare products. The company traces its origins to Ta Chiang International, a trading business established in 1980. During the late 1990s it began building a biomedical and health-product capability, gradually moving away from general trading toward research-led product development and manufacturing. A major strategic change took place in 2011, when TCI shifted from an original design manufacturing model toward a broader CDMO proposition. Under this model, the company works with brand owners from early market and product-concept research through ingredient development, formulation, testing, regulatory support, pilot production, and commercial-scale manufacturing. The approach is designed for private-label and branded-product customers that need an integrated partner rather than a factory providing only a final production step. TCI's service portfolio covers capsules, soft gels, powders, liquid beverages, functional foods, cosmetic preparations, and topical or beauty-oriented formulations. Its research and development activities include functional ingredients, metabolic health, weight management, glycemic control, gut health, probiotics, collagen, beauty-from-within products, and skin-care applications. The company has described its Bio-Resource Data Mining platform as an AI-supported, cloud-based system for identifying potentially useful compounds from natural materials and guiding ingredient discovery. Human studies, laboratory validation, stability testing, and safety assessment form part of the company's product-development claims and commercial support structure. The company has developed or promoted proprietary ingredient and formulation platforms, including GLP-1 Formula for products positioned around endogenous GLP-1 activity, SugarLock for post-meal glucose-management applications, PDRN-based formulations for cosmetic and skin-health uses, and Happy Banana, a standardized banana-peel extract associated with sleep and mood-support research. TCI also promotes liposomal delivery capabilities through its doubleNUTRI platform, intended to improve the formulation and delivery of selected bioactive compounds. TCI has diversified beyond conventional supplement and cosmetic manufacturing. Group activities and affiliated channels have included genetic-testing services through TCI GENE and consumer-oriented retail or product channels associated with TCI Living. This reflects a broader strategy spanning upstream research, ingredient development, contract manufacturing, testing, and downstream consumer access. The company became publicly traded on Taiwan's OTC market in 2013 under stock code 8436, following an earlier public-offering process. Public-market access supported investment in manufacturing capacity, laboratories, overseas business development, and group expansion. During the 2020s, TCI continued to emphasize international customer partnerships, additional research and production facilities, regulatory support for multiple jurisdictions, and sustainability-related manufacturing initiatives. Its customers and commercial relationships extend beyond Taiwan into Asian, European, and North American markets. TCI Bio operates in a competitive and highly regulated sector. It must manage differences in food, supplement, cosmetic, and health-product rules across jurisdictions, while also addressing raw-material supply volatility, production-cost pressure, and customer demand for clinically supported efficacy. Public descriptions of the company place emphasis on integrated scientific development, international compliance, clinical evaluation, and scalable manufacturing rather than on a single consumer product brand.

TCI Bio's corporate history begins in 1980 with the creation of Ta Chiang International, originally a trading company. Its early business was not yet the specialized biotechnology and manufacturing operation associated with the present company. In the late 1990s, the group established a biomedical division and began developing capabilities in health-related products, creating the foundation for later work in functional foods, dietary supplements, cosmetics, and biological ingredients. The company's most important business-model transition occurred in 2011. TCI moved beyond a conventional original design manufacturer role and adopted a contract development and manufacturing organization model. This change broadened the company's responsibilities from producing customer-specified goods to participating in market analysis, concept development, ingredient research, formulation design, laboratory evaluation, clinical-support work, regulatory preparation, pilot production, and full-scale manufacturing. The CDMO model allowed TCI to serve brand owners seeking private-label products or complete product-development programs. TCI obtained access to public capital through Taiwan's OTC market. Its public offering process was associated with 2011, and its shares began trading on September 12, 2013, under code 8436. The listing supported investment in research laboratories, production facilities, capacity expansion, and international business development. The company subsequently developed into a group with multiple business lines and affiliated activities rather than remaining a single manufacturing site. During the 2010s, TCI expanded its work in nutraceuticals, functional beverages, probiotics, collagen, metabolic health, beauty-from-within products, and skincare. It also developed proprietary ingredients and delivery systems intended to give customers differentiated products. Its research agenda included natural-compound discovery, gut microbiome applications, skin health, glycemic management, weight management, and other areas where brands increasingly sought evidence-supported functional claims. TCI describes Bio-Resource Data Mining as an automated, cloud-based and AI-supported platform for analyzing natural resources and identifying candidate bioactive compounds. This technology is part of a larger integrated research process that includes in-vitro work, formulation studies, stability and safety testing, and human clinical evaluation. The company has used this approach in developing ingredients such as GLP-1 Formula, SugarLock, and Happy Banana. Its PDRN work and doubleNUTRI liposomal platform extend the same research-and-delivery emphasis into cosmetic and skin-health applications. The group also diversified into adjacent fields. TCI GENE represents genetic-testing activity, while TCI Living has been associated with consumer-facing retail or product channels. These activities allow the company to participate at several points in the health-product value chain, from research and testing to manufacturing and consumer distribution. In the 2020s, TCI continued to invest in additional laboratories, production capacity, product-development capabilities, and international customer relationships. It has presented itself as a supplier able to support clients in Asia, Europe, North America, and other markets, with regulatory and compliance requirements adapted to different product categories and jurisdictions. Sustainability has also become part of its corporate positioning, including participation in renewable-energy and climate-related initiatives described in industry and corporate materials. The company's ongoing challenges are typical of the international nutraceutical and cosmetic CDMO sector. These include changing regulations, the need for substantiated health and beauty claims, raw-material availability, supply-chain disruption, pressure from lower-cost manufacturers, and the requirement to scale customized products economically. TCI's stated response has been continued investment in research, clinical evidence, regulatory capability, manufacturing infrastructure, and proprietary ingredients.

• 2025

  SugarLock showcased internationally

  [1]TCI Bioen.wikipedia.org

  TCI presented SugarLock and associated clinical findings at SupplySide Global.

• 2020

  Expansion into adjacent health businesses

  [1]TCI Bioen.wikipedia.org

  The group expanded laboratories, manufacturing operations, international partnerships, genetic-testing activities, and consumer-facing channels.

• 2013

  OTC market listing

  [1]TCI Bioen.wikipedia.org

  TCI began trading on Taiwan's OTC market on September 12 under stock code 8436.

• 2011

  Business model shifts to CDMO

  [1]TCI Bioen.wikipedia.org

  TCI moved from an ODM orientation toward integrated contract development and manufacturing services.

• 1990

  Biomedical activities begin to develop

  [1]TCI Bioen.wikipedia.org

  In the late 1990s, the group created a biomedical division and began moving toward health-product research and manufacturing.

• 1980

  Predecessor trading company established

  [1]TCI Bioen.wikipedia.org

  Ta Chiang International, the predecessor of TCI Bio, was established as a trading company.

An integrated, science-led CDMO and ingredient-development partner for functional foods, nutraceuticals, beverages, cosmetics, and beauty-from-within products. TCI Bio positions itself around proprietary bioactive discovery, formulation expertise, clinical validation, regulatory support, and turnkey manufacturing for domestic and international brands.

• Contract development and manufacturing · 2011

  Integrated CDMO services

  TCI's principal offering covers the full development path for functional foods, beverages, dietary supplements, and cosmetics. Services may include market and concept work, ingredient sourcing, proprietary ingredient development, formulation, laboratory testing, stability and safety assessment, pilot batches, regulatory support, and commercial production. The model is intended for brand owners and private-label customers that want one partner to coordinate product development and manufacturing.

• Metabolic-health ingredient and formulation

  GLP-1 Formula

  GLP-1 Formula is a proprietary blend of plant extracts, probiotics, and prebiotics developed for products positioned around the body's natural GLP-1 response. TCI describes its development as involving Bio-Resource Data Mining, laboratory validation, and human studies. The ingredient is intended for metabolic-health, appetite-management, glycemic-control, and fat-metabolism applications, subject to the regulatory requirements of the market in which a finished product is sold.

• Botanical metabolic-health ingredient

  SugarLock

  SugarLock is a polyphenol-rich botanical extract positioned for post-meal glucose and metabolic-health products. TCI has described a six-week human intervention study in which the ingredient was evaluated for effects including fasting glucose, body composition, and postprandial blood-sugar response, with continuous glucose monitoring used as an additional assessment method. It is marketed as an ingredient platform for brands developing glycemic-management concepts.

• Botanical ingredient for sleep and mood applications

  Happy Banana

  Happy Banana is a standardized extract made from banana peel and developed for sleep, mood, and circadian-rhythm applications. TCI has reported extraction and standardization work, in-vitro testing, and randomized controlled human studies examining biomarkers and sleep-related outcomes. The ingredient has also been associated with regulatory notifications and patent activity in several markets.

• Cosmetic and skin-health formulations

  PDRN-based formulations

  TCI incorporates PDRN-based materials into cosmetic and skin-health development. These nucleotide-derived compounds are used in beauty-oriented formulations, but their relatively large molecular size, stability limitations, and delivery challenges require specialized formulation work. TCI's related capabilities include delivery and encapsulation approaches intended to improve the practicality of bioactive cosmetic ingredients.

• Liposomal delivery platform

  doubleNUTRI

  doubleNUTRI is TCI's branded liposomal formulation platform. It is intended to support the delivery and stability of selected nutritional and bioactive compounds in supplement, beverage, and beauty-from-within products. The platform forms part of TCI's broader effort to combine ingredient development with dosage-form and delivery-system expertise.

• Genetic testing and health services

  TCI GENE

  TCI GENE represents the group's diversification into genetic-testing and related health-information services. It extends TCI's activities beyond physical product development into testing and digital-health-related applications, although the precise current scope of services is not established by the supplied reference material.

• 2020

  Diversify into testing, digital health, and consumer channelsStrategy

  Background

  TCI pursued a broader health-product ecosystem rather than relying exclusively on contract manufacturing.

  Action taken

  The group developed or expanded activities associated with genetic testing, digital health, and consumer-oriented channels alongside its core CDMO operations.

  Aftermath

  The strategy broadened the group's presence across research, testing, manufacturing, and downstream product access.

  Source

• 2013

  List shares on Taiwan's OTC marketOther

  Background

  TCI required additional capital and public-market visibility to support capacity expansion, research investment, and overseas development.

  Action taken

  The company listed on Taiwan's OTC market on September 12, 2013, under stock code 8436.

  Aftermath

  The listing increased access to capital and accompanied the company's development into a larger, more diversified CDMO group.

  Source

• 2011

  Adopt an integrated CDMO strategyStrategy

  Background

  TCI sought to move beyond ODM production and capture more value in research, proprietary ingredients, formulation, testing, regulatory preparation, and manufacturing.

  Action taken

  The company reorganized its commercial emphasis around contract development and manufacturing services for functional foods, supplements, beverages, and cosmetics.

  Aftermath

  The shift became the foundation for international customer partnerships, expanded laboratories and factories, and a broader product-development portfolio.

  Source

• 2025

  SugarLock ingredient presented at SupplySide Global[1]TCI Bioen.wikipedia.org

  Product launch · Campaign

  TCI presented SugarLock, a botanical ingredient positioned for glycemic-control and metabolic-health applications, together with findings from a six-week human intervention study and continuous glucose-monitoring evaluation.

• 2020

  TCI Bio expands research, manufacturing, and international CDMO activities[1]TCI Bioen.wikipedia.org

  Other

  During the 2020s, TCI expanded laboratories, manufacturing capacity, product categories, and international partnerships while developing activities in genetic testing, digital health, and consumer channels.

• 2013

  TCI Bio begins trading on Taiwan's OTC market[1]TCI Bioen.wikipedia.org

  Other

  The company was listed on Taiwan's over-the-counter market on September 12, 2013, under stock code 8436.

• 2011

  TCI Bio transitions toward a contract development and manufacturing model[1]TCI Bioen.wikipedia.org

  Other

  TCI changed its strategic emphasis from original design manufacturing toward contract development and manufacturing, combining research, proprietary ingredients, formulation, testing, and production services.

1. 1TCI Bioen.wikipedia.org
2. 2大江生醫擬花6億 公開收購和康生技3成股權 | 財經 | 三立新聞網 SETN.COMsetn.com